LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Inicio・Lista de Acciones・Amgen Inc

Amgen Inc

Cerrado

SectorSanidad

326.2 -3.03

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

325.13

Máximo

336.3

Métricas clave
By Trading Economics
Ingresos	486M 1.8B
Ventas	-1.3B 8.6B
P/B Media del Sector	22.936 51.415
BPA	5.15
Rentabilidad por dividendo	2.91
Margen de beneficios	21.107
Empleados	31,500
EBITDA	-2.3B 2.7B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+8.47% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	2.91% 2.34%
Próximas Ganancias	4 ago 2026
Fecha Próximo Dividendo	5 jun 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-5.4B 178B
Apertura anterior	329.23
Cierre anterior	326.2

Noticias sobre sentimiento de mercado

By Acuity

32%

68%

81 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

270.44 / 276.44 Soporte y Resistencia

Amgen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

30 abr 2026, 20:16 UTC

Ganancias

Amgen Posts Higher 1Q Profit, Revenue

6 abr 2026, 17:09 UTC

Principales Movimientos del Mercado

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

3 feb 2026, 21:49 UTC

Ganancias

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

6 ene 2026, 15:14 UTC

Adquisiciones, fusiones, absorciones

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19 nov 2025, 21:55 UTC

Principales Movimientos del Mercado

Amgen Lung Cancer Drug Gets Full Approval From FDA

30 abr 2026, 20:01 UTC

Ganancias

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

30 abr 2026, 20:01 UTC

Ganancias

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

30 abr 2026, 20:01 UTC

Ganancias

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

30 abr 2026, 20:01 UTC

Ganancias

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

30 abr 2026, 20:01 UTC

Ganancias

Amgen 1Q Adj EPS $5.15 >AMGN

30 abr 2026, 20:01 UTC

Ganancias

Amgen 1Q Rev $8.62B >AMGN

30 abr 2026, 20:01 UTC

Ganancias

Amgen 1Q Net $1.82B >AMGN

30 abr 2026, 20:01 UTC

Ganancias

Amgen 1Q EPS $3.34 >AMGN

1 abr 2026, 20:07 UTC

Adquisiciones, fusiones, absorciones

Why 2026 Is Biotech's Comeback Year -- Barrons.com

4 feb 2026, 19:56 UTC

Charlas de Mercado

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

3 feb 2026, 21:01 UTC

Ganancias

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen 4Q Adj EPS $5.29 >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen 4Q Net $1.33B >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen 4Q Rev $9.9B >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen Sees FY Rev $37B-$38.4B >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

3 feb 2026, 21:01 UTC

Ganancias

Amgen 4Q EPS $2.45 >AMGN

28 ene 2026, 17:47 UTC

Ganancias

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

6 ene 2026, 14:01 UTC

Adquisiciones, fusiones, absorciones

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6 ene 2026, 14:01 UTC

Adquisiciones, fusiones, absorciones

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6 ene 2026, 14:00 UTC

Adquisiciones, fusiones, absorciones

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Comparación entre iguales

Cambio de precio

Amgen Inc previsión

Precio Objetivo

By TipRanks

8.47% repunte

Estimación a 12 Meses

Media 364.7 USD 8.47%

Máximo 427 USD

Mínimo 300 USD

De acuerdo con 24 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amgen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

24 ratings

Comprar

Mantener

Vender

De acuerdo con 24 analistas que ofrecen calificaciones bursátiles a para Amgen Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

270.44 / 276.44Soporte y Resistencia

Recent bearish events outweigh bullish events.

Sentimiento

By Acuity

81 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.